Owen A O'Connor

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Hematol 43:251-61. 2006
  2. ncbi request reprint Pralatrexate: an emerging new agent with activity in T-cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Department of Medicine, Division of Hematologic Malignancies, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Curr Opin Oncol 18:591-7. 2006
  3. ncbi request reprint The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Owen A O'Connor
    Department of Medicine, Lymphoma, and Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:2902-11. 2006
  4. ncbi request reprint Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    Owen A O'Connor
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Clin Lymphoma Myeloma 6:191-9. 2005
  5. ncbi request reprint Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
  6. ncbi request reprint Targeting histones and proteasomes: new strategies for the treatment of lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave, New York, NY 1002, USA
    J Clin Oncol 23:6429-36. 2005
  7. ncbi request reprint Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center
    Leuk Lymphoma 46:973-92. 2005
  8. ncbi request reprint Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
  9. ncbi request reprint The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Malignancies, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Treat Options Oncol 5:269-81. 2004
  10. doi request reprint The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008

Detail Information

Publications50

  1. ncbi request reprint New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Hematol 43:251-61. 2006
    ....
  2. ncbi request reprint Pralatrexate: an emerging new agent with activity in T-cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Department of Medicine, Division of Hematologic Malignancies, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Curr Opin Oncol 18:591-7. 2006
    ..Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1 (RFC-1). Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL...
  3. ncbi request reprint The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Owen A O'Connor
    Department of Medicine, Lymphoma, and Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:2902-11. 2006
    ..To determine whether the combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen can sensitize human lymphoma to cyclophosphamide...
  4. ncbi request reprint Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    Owen A O'Connor
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Clin Lymphoma Myeloma 6:191-9. 2005
    ..Herein, some of the biologic rationale for using proteasome inhibitors in lymphoma as well as some of the clinical data from these promising studies are discussed...
  5. ncbi request reprint Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  6. ncbi request reprint Targeting histones and proteasomes: new strategies for the treatment of lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave, New York, NY 1002, USA
    J Clin Oncol 23:6429-36. 2005
    ..In this article, we will review some of the prevailing theories about how these novel targeted drugs affect lymphoma biology, and how these compounds are changing the face of lymphoma therapy...
  7. ncbi request reprint Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center
    Leuk Lymphoma 46:973-92. 2005
    ..In this article, we will review the numerous complexities associated with various animal models of lymphoma, and will try to explore several alternative models which might serve as better in vivo...
  8. ncbi request reprint Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL)...
  9. ncbi request reprint The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Malignancies, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Treat Options Oncol 5:269-81. 2004
    ..The story is testament to the value of recognizing the importance of empiric observations in clinical and preclinical investigations...
  10. doi request reprint The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008
    ..Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies...
  11. doi request reprint Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Clin Cancer Res 16:554-65. 2010
    ..They are also known to be prodifferentiating. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) translocation leading to the overexpression of cyclin D1...
  12. doi request reprint Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
    Owen A O'Connor
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Br J Haematol 145:34-9. 2009
    ..Importantly, these data suggest that MCL patients with refractory or poorly responsive disease may still derive meaningful clinical benefit from treatment with bortezomib...
  13. doi request reprint Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
    Owen A O'Connor
    NYU Cancer Institute, NYU Langone Medical Center, New York, New York, USA
    Clin Cancer Res 16:719-26. 2010
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma...
  14. doi request reprint Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 17:2493-501. 2011
    ....
  15. pmc Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  16. doi request reprint A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10032, USA
    Br J Haematol 143:201-9. 2008
    ..The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma...
  17. doi request reprint Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA
    Br J Haematol 146:652-5. 2009
    ..The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients...
  18. pmc Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Owen A O'Connor
    Lymphoid Development and Malignancy Program, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032, USA
    J Clin Oncol 27:4357-64. 2009
    ..To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma...
  19. doi request reprint Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
    Steven M Horwitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Blood 119:4115-22. 2012
    ..The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high activity with acceptable toxicity in patients with relapsed/refractory CTCL...
  20. doi request reprint Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions
    Alexander G Marneros
    Department of Dermatology, Columbia Presbyterian Medical Center, New York, NY, USA
    Blood 113:6338-41. 2009
    ..This distinction is critical and may profoundly influence the clinical decision to continue pralatrexate treatment. Pralatrexate-induced skin erosions may indicate response to treatment...
  21. ncbi request reprint Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Owen A O'Connor
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA
    Br J Haematol 139:425-8. 2007
    ..For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL...
  22. doi request reprint The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Br J Haematol 146:656-9. 2009
    ..In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone...
  23. ncbi request reprint Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:391-8. 2006
    ..In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients...
  24. doi request reprint Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Blood 111:5350-8. 2008
    ..The addition of AT-101 to cyclophosphamide (Cy) and rituximab (R) in a schedule-dependent manner enhanced the efficacy of the conventional therapy...
  25. pmc HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
    Matko Kalac
    New York University Cancer Institute, New York University Langone Medical Center, 522 First Avenue, New York, NY 10016, USA
    Blood 118:5506-16. 2011
    ..Among the genes uniquely altered by the combination of panobinostat and decitabine were VHL, TCEB1, WT1, and DIRAS3...
  26. pmc Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
    Mark L Heaney
    Departments of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:8031-8. 2008
    ..These results support the hypothesis that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response...
  27. ncbi request reprint Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Robert Z Orlowski
    Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7295, USA
    J Clin Oncol 20:4420-7. 2002
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies...
  28. doi request reprint Novel agents in development for peripheral T-cell lymphoma
    Owen A O'Connor
    New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    Semin Hematol 47:S11-4. 2010
    ....
  29. doi request reprint Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies
    Enrica Marchi
    New York University Cancer Institute, NYU Langone Medical Center, New York, New York 10016, USA
    Clin Cancer Res 16:3648-58. 2010
    ..Based on the PROPEL data, pralatrexate was the first drug approved for patients with relapsed and refractory peripheral T-cell lymphoma. Bortezomib is a proteasome inhibitor that has shown some activity in patients with T-cell lymphoma...
  30. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  31. ncbi request reprint Targeting survival pathways in lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, The New York Presbyterian Hospital, Columbia University, New York, USA
    Adv Exp Med Biol 687:79-96. 2010
    ..Appropriate preclinical studies will need to identify the optimal strategies for combining these agents, with an emphasis on the importance of dose and schedule dependency...
  32. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  33. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  34. doi request reprint A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
    Owen A O'Connor
    NYU Cancer Institute, NYU Langone Medical Center, 522 First Ave, Smilow 1101, New York, NY, USA
    Clin Cancer Res 15:7085-91. 2009
    ..Proteasome inhibition by carfilzomib is mechanistically irreversible. Consequently, proteasome inhibition is more sustained with carfilzomib than with bortezomib...
  35. doi request reprint New drugs for the treatment of lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, Room 216, New York, NY 10032, USA
    Hematol Oncol Clin North Am 22:1007-35, x. 2008
    ..The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway...
  36. doi request reprint Brentuximab vedotin
    Changchun Deng
    Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY 10022, USA
    Clin Cancer Res 19:22-7. 2013
    ..The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed...
  37. doi request reprint Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
    Jason Konner
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 30:2294-302. 2012
    ..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma...
  38. pmc Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
    Owen A O'Connor
    New York University NYU Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    J Clin Oncol 29:1182-9. 2011
    ..Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity...
  39. doi request reprint Murine models in mantle cell lymphoma
    Kelly Zullo
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    Best Pract Res Clin Haematol 25:153-63. 2012
    ....
  40. doi request reprint Mantle cell lymphoma in relapse: the role of emerging new drugs
    Catherine S M Diefenbach
    New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    Curr Opin Oncol 22:419-23. 2010
    ..Advances in our understanding of the molecular pathogenesis of MCL are yielding many promising novel therapies...
  41. doi request reprint A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score
    Adrienne A Phillips
    Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, Milstein Hospital Building, New York, New York 10032, USA
    Cancer 116:3438-46. 2010
    ....
  42. doi request reprint New therapeutic targets and drugs in non-Hodgkin's lymphoma
    Ahmed Sawas
    NYU Cancer Institute, School of Medicine, NYU Langone Medical Center, New York, New York 10016, USA
    Curr Opin Hematol 18:280-7. 2011
    ..Advances in our understanding of lymphoma biology and molecular pathogenesis are yielding new therapeutic targets...
  43. doi request reprint Acute orbitocranial inflammation following radioimmunotherapy for non-Hodgkin lymphoma
    John C Hwang
    Edward S Harkness Eye Institute, Columbia University Medical Center, New York, New York 10032, USA
    Ophthal Plast Reconstr Surg 26:210-2. 2010
    ..Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan may result in hemorrhagic tumor necrosis with acute orbital and intracranial inflammation...
  44. ncbi request reprint Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 47:1260-4. 2006
    ..9%). PegIFN plus rituximab as delivered in this study is not recommended. PegIFN does not appear to upregulate CD20 expression in peripheral lymph node tumor cells...
  45. doi request reprint Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
    Francesca Montanari
    Department of Internal Medicine Division of Hematology Oncology, Columbia University, New York, NY 10032, USA
    Hum Pathol 41:1150-8. 2010
    ....
  46. pmc Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 117:4530-41. 2011
    ..Significant in vivo therapeutic activity of combination rituximab and milatuzumab was demonstrated in a preclinical model of MCL. These data support clinical evaluation of combination milatuzumab and rituximab therapy in MCL...
  47. pmc Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Enrica Marchi
    Associate Research Scientist, Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
    Ther Adv Hematol 3:227-35. 2012
    ..clinical development, pralatrexate, preclinical data, T-cell lymphoma...
  48. doi request reprint New strategies in the treatment of mantle cell lymphoma
    Changchun Deng
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York 10022, USA
    Clin Cancer Res 18:3499-508. 2012
    ..Here, we discuss many of these developments and how they may potentially affect the natural history of this disease...
  49. pmc Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
    Salvia Jain
    NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USA
    Core Evid 6:43-57. 2011
    ..This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-exposed populations...
  50. pmc Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
    Jasmine Zain
    NYU Clinical Cancer Center, 160 East 34th Street, New York, NY 10016, USA
    Invest New Drugs 28:S58-78. 2010
    ..HDAC inhibitors will likely be incorporated into combinations of targeted therapies both in the upfront and relapsed setting for lymphomas...